CD8A and neoplasm: The sponsor decided to discontinue the development of FAP-IL2v for strategic reasons; however, alternative approaches for simultaneous targeting of PD-1 and IL2-receptors (e.g., on PD-1+ T stem–like cells) and the capability of IL2 to rewire exhausted CD8 T cells (29) warrant further investigation in immunogenic, T cell-infiltrated active tumor types such as melanoma and others.